Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$181.89 -2.6%	$186.21	$163.52 ▼ $218.66	$329.95B	0.5	6.32 million shs	29.26 million shs
BMY Bristol Myers Squibb	$46.34 -0.7%	$47.90	$39.35 ▼ $63.33	$94.94B	0.38	12.92 million shs	21.85 million shs
JNJ Johnson & Johnson	$152.44 +0.3%	$153.75	$140.68 ▼ $169.99	$365.75B	0.42	8.03 million shs	10.00 million shs
MRK Merck & Co., Inc.	$78.93 +0.1%	$79.06	$73.31 ▼ $130.97	$197.94B	0.38	13.33 million shs	60.17 million shs
PFE Pfizer	$24.20 -0.2%	$23.46	$20.92 ▼ $31.54	$137.81B	0.57	41.34 million shs	39.50 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-2.76%	-1.77%	-0.60%	-11.33%	+6.27%
BMY Bristol Myers Squibb	-0.73%	-1.12%	-1.36%	-22.89%	+9.04%
JNJ Johnson & Johnson	+0.12%	+1.76%	-0.06%	-6.84%	+3.83%
MRK Merck & Co., Inc.	-0.01%	-0.40%	+3.62%	-11.49%	-39.98%
PFE Pfizer	-0.44%	+0.95%	+4.38%	-3.99%	-11.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.961 of 5 stars	3.4	5.0	4.2	3.9	3.0	2.5	1.3
BMY Bristol Myers Squibb	4.9853 of 5 stars	4.2	3.0	4.2	4.0	3.4	3.3	1.3
JNJ Johnson & Johnson	4.9625 of 5 stars	3.3	5.0	4.2	3.9	3.0	1.7	1.9
MRK Merck & Co., Inc.	4.9948 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
PFE Pfizer	4.8653 of 5 stars	2.3	3.0	4.2	4.3	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	16.16% Upside
BMY Bristol Myers Squibb	2.32	Hold	$58.00	25.16% Upside
JNJ Johnson & Johnson	2.55	Moderate Buy	$170.88	12.10% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	38.33% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.54% Upside

Current Analyst Ratings Breakdown

Latest ABBV, JNJ, BMY, PFE, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/13/2025	JNJ Johnson & Johnson	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.70	$14.54 per share	12.51	$1.90 per share	95.73
BMY Bristol Myers Squibb	$48.30B	1.95	$5.85 per share	7.92	$8.08 per share	5.74
JNJ Johnson & Johnson	$88.82B	4.13	$13.15 per share	11.59	$29.69 per share	5.13
MRK Merck & Co., Inc.	$64.17B	3.09	$9.48 per share	8.33	$18.33 per share	4.31
PFE Pfizer	$63.63B	2.16	$4.36 per share	5.55	$15.62 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	77.40	13.01	1.24	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.36	7.61	1.38	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$8.99	16.96	13.77	2.30	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.49	7.97	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.53	7.99	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest ABBV, JNJ, BMY, PFE, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.61%	N/A	279.15%	53 Years
BMY Bristol Myers Squibb	$2.48	5.35%	N/A	92.88%	17 Years
JNJ Johnson & Johnson	$5.20	3.41%	N/A	57.84%	64 Years
MRK Merck & Co., Inc.	$3.24	4.10%	N/A	47.16%	14 Years
PFE Pfizer	$1.72	7.11%	N/A	124.64%	16 Years

Latest ABBV, JNJ, BMY, PFE, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
BMY Bristol Myers Squibb	2.65	1.28	1.17
JNJ Johnson & Johnson	0.49	1.26	1.03
MRK Merck & Co., Inc.	0.69	1.41	1.16
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol Myers Squibb	76.41%
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol Myers Squibb	0.09%
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.13%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

ABBV, JNJ, BMY, PFE, and MRK Headlines

Recent News About These Companies

Pfizer’s Bold Clinical Trials Could Boost Stock Performance

5 hours ago | tipranks.com

Sumitomo Mitsui Trust Group Inc. Sells 941,490 Shares of Pfizer Inc. (NYSE:PFE)

June 28 at 8:17 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Sunbelt Securities Inc.

June 28 at 6:56 AM | marketbeat.com

Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment

June 28 at 6:38 AM | msn.com

3 No-Brainer Stocks to Buy for Under $100 Right Now

June 28 at 6:35 AM | fool.com

BSW Wealth Partners Acquires 17,274 Shares of Pfizer Inc. (NYSE:PFE)

June 28 at 6:30 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by QSM Asset Management Ltd

June 28 at 5:44 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Achmea Investment Management B.V.

June 28 at 5:26 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Illinois Municipal Retirement Fund

June 28 at 5:17 AM | marketbeat.com

Perpetual Ltd Grows Stake in Pfizer Inc. (NYSE:PFE)

June 28 at 4:46 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Holdings Lifted by Bessemer Group Inc.

June 28 at 4:03 AM | marketbeat.com

Pfizer reports positive results from Phase III BAISIS trial for haemophilia

June 27 at 8:37 PM | msn.com

5 Recession-Proof Dividend Stocks With Yields Over 6%

June 27 at 4:15 PM | 247wallst.com

Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies

June 27 at 3:35 PM | msn.com

Pfizer’s New Clinical Study on PF-07985631: A Potential Game-Changer for Kidney Disease

June 27 at 12:56 PM | tipranks.com

Pfizer’s Prevnar 20 Study: A Potential Game-Changer for Elderly Pneumonia Prevention

June 27 at 12:09 PM | tipranks.com

PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal

June 27 at 12:00 PM | zacks.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Philip James Wealth Mangement LLC

June 27 at 8:17 AM | marketbeat.com

Quilter Plc Reduces Stake in Pfizer Inc. (NYSE:PFE)

June 27 at 8:06 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Artemis Investment Management LLP

June 27 at 7:55 AM | marketbeat.com

Pfizer Reveals Positive Phase 3 Results for HYMPAVZI

June 27 at 7:33 AM | miragenews.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABBV, JNJ, BMY, PFE, and MRK Company Descriptions

AbbVie NYSE:ABBV

$181.89 -4.90 (-2.62%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$182.78 +0.89 (+0.49%)

As of 06/27/2025 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$46.34 -0.31 (-0.66%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$46.30 -0.05 (-0.10%)

As of 06/27/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson NYSE:JNJ

$152.44 +0.43 (+0.28%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$152.62 +0.19 (+0.12%)

As of 06/27/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$78.93 +0.10 (+0.13%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$79.00 +0.07 (+0.10%)

As of 06/27/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.20 -0.04 (-0.18%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$24.18 -0.02 (-0.07%)

As of 06/27/2025 08:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time